

Reconstruction of antibody dynamics and infection hist

Nature

557, 719-723

DOI: [10.1038/s41586-018-0157-4](https://doi.org/10.1038/s41586-018-0157-4)

Citation Report

#	ARTICLE	IF	CITATIONS
1	A Combination of Two Human Monoclonal Antibodies Prevents Zika Virus Escape Mutations in Non-human Primates. <i>Cell Reports</i> , 2018, 25, 1385-1394.e7.	2.9	61
2	Risk of Dengue in Travelers: Implications for Dengue Vaccination. <i>Current Infectious Disease Reports</i> , 2018, 20, 50.	1.3	17
3	Dengue: a growing threat requiring vaccine development for disease prevention. <i>Pathogens and Global Health</i> , 2018, 112, 294-305.	1.0	32
4	Assessment of benefits and risks associated with dengue vaccination at the individual and population levels: a dynamic modeling approach. <i>Expert Review of Vaccines</i> , 2018, 17, 753-763.	2.0	3
5	Challenges and opportunities in controlling mosquito-borne infections. <i>Nature</i> , 2018, 559, 490-497.	13.7	111
6	Serostatus-dependent performance of the first licensed dengue vaccine: implications for travellers. <i>Journal of Travel Medicine</i> , 2018, 25, .	1.4	33
7	Severe dengue in travellers: pathogenesis, risk and clinical management. <i>Journal of Travel Medicine</i> , 2019, 26, .	1.4	86
8	Risk of Zika microcephaly correlates with features of maternal antibodies. <i>Journal of Experimental Medicine</i> , 2019, 216, 2302-2315.	4.2	41
9	A Modified mRNA Vaccine Targeting Immunodominant NS Eitopes Protects Against Dengue Virus Infection in HLA Class I Transgenic Mice. <i>Frontiers in Immunology</i> , 2019, 10, 1424.	2.2	59
10	Molecular Simulations Reveal the Role of Antibody Fine Specificity and Viral Maturation State on Antibody-Dependent Enhancement of Infection in Dengue Virus. <i>Frontiers in Cellular and Infection Microbiology</i> , 2019, 9, 200.	1.8	13
11	Thermal biology of mosquito-borne disease. <i>Ecology Letters</i> , 2019, 22, 1690-1708.	3.0	349
12	Cross-Reactive T Cell Immunity to Dengue and Zika Viruses: New Insights Into Vaccine Development. <i>Frontiers in Immunology</i> , 2019, 10, 1316.	2.2	51
13	Cross-serotype interactions and disease outcome prediction of dengue infections in Vietnam. <i>Scientific Reports</i> , 2019, 9, 9395.	1.6	33
14	West Nile Virus and Usutu Virus Co-Circulation in Europe: Epidemiology and Implications. <i>Microorganisms</i> , 2019, 7, 184.	1.6	58
15	Longitudinal Analysis of Memory B and T Cell Responses to Dengue Virus in a 5-Year Prospective Cohort Study in Thailand. <i>Frontiers in Immunology</i> , 2019, 10, 1359.	2.2	11
16	A review of Dengvaxia®: development to deployment. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 2295-2314.	1.4	206
17	Tracking the polyclonal neutralizing antibody response to a dengue virus serotype 1 type-specific epitope across two populations in Asia and the Americas. <i>Scientific Reports</i> , 2019, 9, 16258.	1.6	10
18	West Nile virus infection in individuals with pre-existing Usutu virus immunity, northern Italy, 2018. <i>Eurosurveillance</i> , 2019, 24, .	3.9	18

#	ARTICLE	IF	CITATIONS
19	Selective Detection of Dengue Virus Serotypes Using Tandem Toehold-Mediated Displacement Reactions. <i>ACS Infectious Diseases</i> , 2019, 5, 1907-1914.	1.8	10
20	Dengue. <i>Lancet, The</i> , 2019, 393, 350-363.	6.3	420
21	Influence of chemokines on the endothelial permeability and cellular transmigration during dengue. <i>Immunology Letters</i> , 2019, 212, 88-97.	1.1	5
22	Serologic Tools and Strategies to Support Intervention Trials to Combat Zika Virus Infection and Disease. <i>Tropical Medicine and Infectious Disease</i> , 2019, 4, 68.	0.9	11
23	Detection of post-vaccination enhanced dengue virus infection in macaques: An improved model for early assessment of dengue vaccines. <i>PLoS Pathogens</i> , 2019, 15, e1007721.	2.1	27
24	Effects of infection history on dengue virus infection and pathogenicity. <i>Nature Communications</i> , 2019, 10, 1246.	5.8	26
25	An antiviral drug screening system for enterovirus 71 based on an improved plaque assay: A potential high-throughput method. <i>Journal of Medical Virology</i> , 2019, 91, 1440-1447.	2.5	12
26	Antigenic cross-reactivity between Zika and dengue viruses: is it time to develop a universal vaccine?. <i>Current Opinion in Immunology</i> , 2019, 59, 1-8.	2.4	37
27	Global expansion and redistribution of Aedes-borne virus transmission risk with climate change. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007213.	1.3	484
28	Recent advances in understanding dengue. <i>F1000Research</i> , 2019, 8, 1279.	0.8	63
29	Impaired Antibody-Independent Immune Response of B Cells in Patients With Acute Dengue Infection. <i>Frontiers in Immunology</i> , 2019, 10, 2500.	2.2	12
30	The first licensed dengue vaccine. <i>Current Opinion in Infectious Diseases</i> , 2019, 32, 394-400.	1.3	13
31	Dengue in hospitalized children with sickle cell disease: A retrospective cohort study in the French departments of America. <i>Journal of Infection and Public Health</i> , 2020, 13, 186-192.	1.9	17
32	The Global Expansion of Dengue: How <i>Aedes aegypti</i> Mosquitoes Enabled the First Pandemic Arbovirus. <i>Annual Review of Entomology</i> , 2020, 65, 191-208.	5.7	203
33	Zika Virus Infection in Pregnancy: Advanced Diagnostic Approaches in Dengue-Naive and Dengue-Experienced Pregnant Women and Possible Implication for Cross-Reactivity and Cross-Protection. <i>Microorganisms</i> , 2020, 8, 56.	1.6	3
34	Re-emergence of dengue virus serotype 3 infections in Gabon in 2016–2017, and evidence for the risk of repeated dengue virus infections. <i>International Journal of Infectious Diseases</i> , 2020, 91, 129-136.	1.5	29
35	Protective and enhancing interactions among dengue viruses 1-4 and Zika virus. <i>Current Opinion in Virology</i> , 2020, 43, 59-70.	2.6	41
36	Antibody-Dependent Enhancement: A Challenge for Developing a Safe Dengue Vaccine. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 572681.	1.8	103

#	ARTICLE	IF	CITATIONS
37	The role of IgG Fc receptors in antibody-dependent enhancement. <i>Nature Reviews Immunology</i> , 2020, 20, 633-643.	10.6	340
38	Japanese encephalitis virus-primed CD8+ T cells prevent antibody-dependent enhancement of Zika virus pathogenesis. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	10
39	Fine-scale heterogeneity in <i>Schistosoma mansoni</i> force of infection measured through antibody response. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 23174-23181.	3.3	14
40	Protection against dengue virus requires a sustained balance of antibody and T cell responses. <i>Current Opinion in Virology</i> , 2020, 43, 22-27.	2.6	3
41	Dengue and Zika virus infections are enhanced by live attenuated dengue vaccine but not by recombinant DSV4 vaccine candidate in mouse models. <i>EBioMedicine</i> , 2020, 60, 102991.	2.7	21
42	Zika virus infection enhances future risk of severe dengue disease. <i>Science</i> , 2020, 369, 1123-1128.	6.0	171
43	Climate change could shift disease burden from malaria to arboviruses in Africa. <i>Lancet Planetary Health</i> , The, 2020, 4, e416-e423.	5.1	163
44	A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity. <i>Nature Communications</i> , 2020, 11, 4704.	5.8	775
45	Risk of dengue virus infection according to serostatus in individuals from dengue endemic areas of Mexico. <i>Scientific Reports</i> , 2020, 10, 19017.	1.6	6
46	Autoantibody Profiling in Plasma of Dengue Virus-Infected Individuals. <i>Pathogens</i> , 2020, 9, 1060.	1.2	6
47	Protective Immunity to Dengue Virus Induced by DNA Vaccines Encoding Nonstructural Proteins in a Lethal Challenge Immunocompetent Mouse Model. <i>Frontiers in Medical Technology</i> , 2020, 2, 558984.	1.3	2
48	ADE and hyperinflammation in SARS-CoV2 infection- comparison with dengue hemorrhagic fever and feline infectious peritonitis. <i>Cytokine</i> , 2020, 136, 155256.	1.4	26
49	Hidden heterogeneity and its influence on dengue vaccination impact. <i>Infectious Disease Modelling</i> , 2020, 5, 783-797.	1.2	2
50	CD8 ⁺ T cells mediate protection against Zika virus induced by an NS3-based vaccine. <i>Science Advances</i> , 2020, 6, .	4.7	20
51	An open source tool to infer epidemiological and immunological dynamics from serological data: serosolver. <i>PLoS Computational Biology</i> , 2020, 16, e1007840.	1.5	13
52	The dynamics of antibodies to SARS-CoV-2 in a case of SARS-CoV-2 infection. <i>International Journal of Infectious Diseases</i> , 2020, 96, 359-360.	1.5	2
53	Antibody-Dependent Enhancement of Severe Disease Is Mediated by Serum Viral Load in Pediatric Dengue Virus Infections. <i>Journal of Infectious Diseases</i> , 2020, 221, 1846-1854.	1.9	29
54	The Effects of Pre-Existing Antibodies on Live-Attenuated Viral Vaccines. <i>Viruses</i> , 2020, 12, 520.	1.5	47

#	ARTICLE	IF	CITATIONS
55	Identification of Dengue Virus Serotype 3 Specific Antigenic Sites Targeted by Neutralizing Human Antibodies. <i>Cell Host and Microbe</i> , 2020, 27, 710-724.e7.	5.1	25
56	Pre-existing chikungunya virus neutralizing antibodies correlate with risk of symptomatic infection and subclinical seroconversion in a Philippine cohort. <i>International Journal of Infectious Diseases</i> , 2020, 95, 167-173.	1.5	20
57	Combine dengue vaccines to optimize effectiveness. <i>Vaccine</i> , 2020, 38, 4801-4804.	1.7	6
58	Spatiotemporal variability in dengue transmission intensity in Jakarta, Indonesia. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008102.	1.3	15
59	Infection severity across scales in multi-strain immuno-epidemiological Dengue model structured by host antibody level. <i>Journal of Mathematical Biology</i> , 2020, 80, 1803-1843.	0.8	21
60	Primary and Secondary Dengue Virus Infections Elicit Similar Memory B-Cell Responses, but Breadth to Other Serotypes and Cross-Reactivity to Zika Virus Is Higher in Secondary Dengue. <i>Journal of Infectious Diseases</i> , 2020, 222, 590-600.	1.9	17
61	Using cluster analysis to reconstruct dengue exposure patterns from cross-sectional serological studies in Singapore. <i>Parasites and Vectors</i> , 2020, 13, 32.	1.0	8
62	Towards Predicting Progression to Severe Dengue. <i>Trends in Microbiology</i> , 2020, 28, 478-486.	3.5	10
63	An Innovative, Prospective, Hybrid Cohort-Cluster Study Design to Characterize Dengue Virus Transmission in Multigenerational Households in Kamphaeng Phet, Thailand. <i>American Journal of Epidemiology</i> , 2020, 189, 648-659.	1.6	12
64	Mapping global variation in dengue transmission intensity. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	131
65	CD4+ T Cells Cross-Reactive with Dengue and Zika Viruses Protect against Zika Virus Infection. <i>Cell Reports</i> , 2020, 31, 107566.	2.9	31
66	A combination of two human monoclonal antibodies limits fetal damage by Zika virus in macaques. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 7981-7989.	3.3	24
67	When Can One Vaccinate with a Live Vaccine after Wild-Type Dengue Infection?. <i>Vaccines</i> , 2020, 8, 174.	2.1	3
68	The "lifecycle" of human beings: a call to explore vector-borne diseases from an ecosystem perspective. <i>Infectious Diseases of Poverty</i> , 2020, 9, 37.	1.5	2
69	CYD Tetravalent Dengue Vaccine Performance by Baseline Immune Profile (Monotypic/Multitypic) in Dengue-Seropositive Individuals. <i>Clinical Infectious Diseases</i> , 2021, 72, 1730-1737.	2.9	5
70	Developments in statistical inference when assessing spatiotemporal disease clustering with the tau statistic. <i>Spatial Statistics</i> , 2021, 42, 100438.	0.9	3
71	Learning from the past: development of safe and effective COVID-19 vaccines. <i>Nature Reviews Microbiology</i> , 2021, 19, 211-219.	13.6	126
72	Universal Dengue Vaccine Elicits Neutralizing Antibodies against Strains from All Four Dengue Virus Serotypes. <i>Journal of Virology</i> , 2021, 95, .	1.5	6

#	ARTICLE	IF	CITATIONS
73	Evolution and epidemiologic dynamics of dengue virus in Nicaragua during the emergence of chikungunya and Zika viruses. <i>Infection, Genetics and Evolution</i> , 2021, 92, 104680.	1.0	6
76	Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD. <i>Cell Reports</i> , 2021, 34, 108699.	2.9	110
77	Direct Infection of B Cells by Dengue Virus Modulates B Cell Responses in a Cambodian Pediatric Cohort. <i>Frontiers in Immunology</i> , 2020, 11, 594813.	2.2	14
78	Antibody titers against SARS-CoV-2 decline, but do not disappear for several months. <i>EClinicalMedicine</i> , 2021, 32, 100734.	3.2	134
79	Surveillance of the major pathogenic arboviruses of public health concern in Gabon, Central Africa: increased risk of West Nile virus and dengue virus infections. <i>BMC Infectious Diseases</i> , 2021, 21, 265.	1.3	21
80	Climatic and socio-economic factors supporting the co-circulation of dengue, Zika and chikungunya in three different ecosystems in Colombia. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009259.	1.3	28
81	Boosting can explain patterns of fluctuations of ratios of inapparent to symptomatic dengue virus infections. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	8
82	Risk Assessment of Dengue Transmission in Bangladesh Using a Spatiotemporal Network Model and Climate Data. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, 104, 1444-1455.	0.6	12
83	Epidemiology of dengue virus infections in Nepal, 2006â€“2019. <i>Infectious Diseases of Poverty</i> , 2021, 10, 52.	1.5	31
84	Successful management of dengue in renal transplant recipients: A retrospective cohort from a single center. <i>Clinical Transplantation</i> , 2021, 35, e14332.	0.8	1
85	Comparison of Anti-Dengue and Anti-Zika IgG on a Plasmonic Gold Platform with Neutralization Testing. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, 104, 1729-1733.	0.6	3
86	Vectored Immunotherapeutics for Infectious Diseases: Can rAAVs Be The Game Changers for Fighting Transmissible Pathogens?. <i>Frontiers in Immunology</i> , 2021, 12, 673699.	2.2	16
87	Correlation between reported dengue illness history and seropositivity in rural Thailand. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009459.	1.3	2
88	Analysis of Neutralizing Antibodies as a Correlate of Instantaneous Risk of Hospitalized Dengue in Placebo Recipients of Dengue Vaccine Efficacy Trials. <i>Journal of Infectious Diseases</i> , 2022, 225, 332-340.	1.9	1
89	Evaluation of the extended efficacy of the Dengvaxia vaccine against symptomatic and subclinical dengue infection. <i>Nature Medicine</i> , 2021, 27, 1395-1400.	15.2	21
91	Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 233.	7.1	203
92	Impact of prior Dengue immunity on Zika vaccine protection in rhesus macaques and mice. <i>PLoS Pathogens</i> , 2021, 17, e1009673.	2.1	7
93	Antibody fucosylation predicts disease severity in secondary dengue infection. <i>Science</i> , 2021, 372, 1102-1105.	6.0	67

#	ARTICLE	IF	CITATIONS
94	Estimating epidemiologic dynamics from cross-sectional viral load distributions. <i>Science</i> , 2021, 373, .	6.0	148
95	Spatial Distribution and Burden of Emerging Arboviruses in French Guiana. <i>Viruses</i> , 2021, 13, 1299.	1.5	9
96	Efficacy profile of the CYD-TDV dengue vaccine revealed by Bayesian survival analysis of individual-level phase III data. <i>ELife</i> , 2021, 10, .	2.8	5
97	Knowledge gaps in the epidemiology of severe dengue impede vaccine evaluation. <i>Lancet Infectious Diseases</i> , The, 2022, 22, e42-e51.	4.6	20
99	Previous exposure to dengue virus is associated with increased Zika virus burden at the maternal-fetal interface in rhesus macaques. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009641.	1.3	20
100	Longitudinal Analysis of Dengue Virus-Specific Memory T Cell Responses and Their Association With Clinical Outcome in Subsequent DENV Infection. <i>Frontiers in Immunology</i> , 2021, 12, 710300.	2.2	3
101	Adapting Rapid Diagnostic Tests to Detect Historical Dengue Virus Infections. <i>Frontiers in Immunology</i> , 2021, 12, 703887.	2.2	9
102	Stochastic Model of the Adaptive Immune Response Predicts Disease Severity and Captures Enhanced Cross-Reactivity in Natural Dengue Infections. <i>Frontiers in Immunology</i> , 2021, 12, 696755.	2.2	4
105	Considerations for the 2030 Sustainable Development Goals for dengue. <i>Gates Open Research</i> , 0, 3, 1656.	2.0	3
106	Decreased Type I Interferon Production by Plasmacytoid Dendritic Cells Contributes to Severe Dengue. <i>Frontiers in Immunology</i> , 2020, 11, 605087.	2.2	11
107	Reemergence of dengue virus in Bangladesh: Current fatality and the required knowledge. <i>Tzu Chi Medical Journal</i> , 2020, 32, 227.	0.4	3
108	Bridging Efficacy of a Tetravalent Dengue Vaccine from Children/Adolescents to Adults in Highly Endemic Countries Based on Neutralizing Antibody Response. <i>American Journal of Tropical Medicine and Hygiene</i> , 2019, 101, 164-179.	0.6	9
109	Dengue genetic divergence generates within-serotype antigenic variation, but serotypes dominate evolutionary dynamics. <i>ELife</i> , 2019, 8, .	2.8	38
110	Nationally-representative serostudy of dengue in Bangladesh allows generalizable disease burden estimates. <i>ELife</i> , 2019, 8, .	2.8	58
111	Enteropathogen antibody dynamics and force of infection among children in low-resource settings. <i>ELife</i> , 2019, 8, .	2.8	26
112	Broadly neutralizing human antibodies against dengue virus identified by single B cell transcriptomics. <i>ELife</i> , 2019, 8, .	2.8	44
113	How Antibodies Recognize Pathogenic Viruses: Structural Correlates of Antibody Neutralization of HIV-1, SARS-CoV-2, and Zika. <i>Viruses</i> , 2021, 13, 2106.	1.5	7
114	Dengue and Zika virus infections in children elicit cross-reactive protective and enhancing antibodies that persist long term. <i>Science Translational Medicine</i> , 2021, 13, eabg9478.	5.8	32

#	ARTICLE	IF	CITATIONS
116	Identification and evaluation of 4-anilinoquin(az)olines as potent inhibitors of both dengue virus (DENV) and Venezuelan equine encephalitis virus (VEEV). <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021, 52, 128407.	1.0	13
123	Effects of Accounting for Interval-Censored Antibody Titer Decay on Seroincidence in a Longitudinal Cohort Study of Leptospirosis. <i>American Journal of Epidemiology</i> , 2021, 190, 893-899.	1.6	1
126	A method to estimate probability of disease and vaccine efficacy from clinical trial immunogenicity data. <i>Npj Vaccines</i> , 2021, 6, 133.	2.9	2
128	Cross-sectional cycle threshold values reflect epidemic dynamics of COVID-19 in Madagascar. <i>Epidemics</i> , 2022, 38, 100533.	1.5	8
129	Antigenic evolution of dengue viruses over 20 years. <i>Science</i> , 2021, 374, 999-1004.	6.0	34
130	Model-based assessment of Chikungunya and Oâ€™nyong-nyong virus circulation in Mali in a serological cross-reactivity context. <i>Nature Communications</i> , 2021, 12, 6735.	5.8	4
131	The seroepidemiology of dengue in a US military population based in Puerto Rico during the early phase of the Zika pandemic. <i>PLoS Neglected Tropical Diseases</i> , 2022, 16, e0009986.	1.3	1
132	Host immunity and vaccine development against Dengue virus. , 2022, , .		3
133	Reconstructing antibody dynamics to estimate the risk of influenza virus infection. <i>Nature Communications</i> , 2022, 13, 1557.	5.8	9
134	Characterising spatial patterns of neglected tropical disease transmission using integrated sero-surveillance in Northern Ghana. <i>PLoS Neglected Tropical Diseases</i> , 2022, 16, e0010227.	1.3	7
135	Incorporating temporal distribution of population-level viral load enables real-time estimation of COVID-19 transmission. <i>Nature Communications</i> , 2022, 13, 1155.	5.8	16
136	EVITA Dengue: a cluster-randomized controlled trial to Evaluate the efficacy of Wolbachia-InfecTed Aedes aegypti mosquitoes in reducing the incidence of Arboviral infection in Brazil. <i>Trials</i> , 2022, 23, 185.	0.7	5
137	Development of Novel Dengue NS1 Multiplex Lateral Flow Immunoassay to Differentiate Serotypes in Serum of Acute Phase Patients and Infected Mosquitoes. <i>Frontiers in Immunology</i> , 2022, 13, 852452.	2.2	9
140	A Zika virus mutation enhances transmission potential and confers escape from protective dengue virus immunity. <i>Cell Reports</i> , 2022, 39, 110655.	2.9	20
156	Innate Immune Response to Dengue Virus: Toll-like Receptors and Antiviral Response. <i>Viruses</i> , 2022, 14, 992.	1.5	12
157	Individual, Household, and Community Drivers of Dengue Virus Infection Risk in Kamphaeng Phet Province, Thailand. <i>Journal of Infectious Diseases</i> , 2022, 226, 1348-1356.	1.9	6
158	Beneath the surface: Amino acid variation underlying two decades of dengue virus antigenic dynamics in Bangkok, Thailand. <i>PLoS Pathogens</i> , 2022, 18, e1010500.	2.1	5
159	Assessing the role of multiple mechanisms increasing the age of dengue cases in Thailand. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2115790119.	3.3	16

#	ARTICLE	IF	CITATIONS
160	Evaluation of Antibody-Dependent Fc-Mediated Viral Entry, as Compared With Neutralization, in SARS-CoV-2 Infection. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
161	Estimating typhoid incidence from community-based serosurveys: a multicohort study. <i>Lancet Microbe</i> , The, 2022, 3, e578-e587.	3.4	22
165	Estimating the effect of the wMel release programme on the incidence of dengue and chikungunya in Rio de Janeiro, Brazil: a spatiotemporal modelling study. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 1587-1595.	4.6	24
166	Reconstructing long-term dengue virus immunity in French Polynesia. <i>PLoS Neglected Tropical Diseases</i> , 2022, 16, e0010367.	1.3	1
167	Identifying Recent Cholera Infections Using a Multiplex Bead Serological Assay. <i>MBio</i> , 2022, 13, .	1.8	4
168	Temporal patterns of functional anti-dengue antibodies in dengue infected individuals with different disease outcome or infection history. <i>Scientific Reports</i> , 2022, 12, .	1.6	1
170	Considering waning immunity to better explain dengue dynamics. <i>Epidemics</i> , 2022, 41, 100630.	1.5	3
172	Biologics for dengue prevention: up-to-date. <i>Expert Opinion on Biological Therapy</i> , 0, , 1-15.	1.4	3
174	Dynamics of Anti-influenza Mucosal IgA Over a Season in a Cohort of Individuals Living or Working in a Long-term Care Facility. <i>Journal of Infectious Diseases</i> , 0, , .	1.9	0
177	Serum biomarkers and anti-flavivirus antibodies at presentation as indicators of severe dengue. <i>PLoS Neglected Tropical Diseases</i> , 2023, 17, e0010750.	1.3	3
178	A live dengue virus vaccine carrying a chimeric envelope glycoprotein elicits dual DENV2-DENV4 serotype-specific immunity. <i>Nature Communications</i> , 2023, 14, .	5.8	9
179	Understanding antibody-dependent enhancement in dengue: Are afucosylated IgG1s a concern?. <i>PLoS Pathogens</i> , 2023, 19, e1011223.	2.1	7
193	Flaviviruses: Dengue. , 2023, , 1-65.		0